Literature DB >> 20077178

The use of human deceased donor skin allograft in burn care.

Jorge Leon-Villapalos1, Mohamed Eldardiri, Peter Dziewulski.   

Abstract

Burns are tissue wounds caused by thermal, electrical, chemical cold or radiation injuries. Deep injuries lead to dermal damage that impairs the ability of the skin to heal and regenerate on its own. Skin autografting following burn excision is considered the current gold standard of care, but lack of patient's own donor skin or unsuitability of the wound for autografting may require the temporary use of dressings or skin substitutes to promote wound healing, reduce pain, and prevent infection and abnormal scarring. These alternatives include deceased donor skin allograft, xenograft, cultured epithelial cells and biosynthetic skin substitutes. Allotransplantation is the transplantation of cells, tissues, or organs, sourced from a genetically non-identical member of the same species as the recipient. Human deceased donor skin allografts represent a suitable and much used temporizing option for skin cover following burn injury. The main advantages for its use include dermoprotection and promotion of reepithelialisation of the wound and their ability to act as skin cover until autografting is possible or re-harvesting of donor sites becomes available. Disadvantages of its use include the limited abundance and availability of donors, possible transmission of disease, the eventual rejection by the host and its handling storing, transporting and associated costs of provision. This paper will explore the role of allograft skin in burn care, defining the indications for its use in burn management and the future potential for allograft tissue banking.

Entities:  

Mesh:

Year:  2010        PMID: 20077178     DOI: 10.1007/s10561-009-9152-1

Source DB:  PubMed          Journal:  Cell Tissue Bank        ISSN: 1389-9333            Impact factor:   1.522


  26 in total

1.  Development of a biological scaffold engineered using the extracellular matrix secreted by skeletal muscle cells.

Authors:  Shiloh A Hurd; Nadia M Bhatti; Addison M Walker; Ben M Kasukonis; Jeffrey C Wolchok
Journal:  Biomaterials       Date:  2015-02-11       Impact factor: 12.479

2.  A major burn injury in a liver transplant patient.

Authors:  I Delikonstantinou; B Philp; D Kamel; D Barnes; P Dziewulski
Journal:  Ann Burns Fire Disasters       Date:  2016-09-30

Review 3.  Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions.

Authors:  Saeid Amini-Nik; Yusef Yousuf; Marc G Jeschke
Journal:  Adv Drug Deliv Rev       Date:  2017-07-27       Impact factor: 15.470

4.  Successful treatment of complex traumatic and surgical wounds with a foetal bovine dermal matrix.

Authors:  Ernesto Hayn
Journal:  Int Wound J       Date:  2013-03-04       Impact factor: 3.315

5.  The effects of constant flow bioreactor cultivation and keratinocyte seeding densities on prevascularized organotypic skin grafts based on a fibrin scaffold.

Authors:  Marius Julian Helmedag; Stefan Weinandy; Yvonne Marquardt; Jens Malte Baron; Norbert Pallua; Christoph V Suschek; Stefan Jockenhoevel
Journal:  Tissue Eng Part A       Date:  2014-11-20       Impact factor: 3.845

Review 6.  Isn't it time for a cadaver skin bank in South Africa?

Authors:  A D Rogers; N L Allorto; S Adams; K G Adams; D A Hudson; H Rode
Journal:  Ann Burns Fire Disasters       Date:  2013-09-30

Review 7.  Hypertrophic scarring: the greatest unmet challenge after burn injury.

Authors:  Celeste C Finnerty; Marc G Jeschke; Ludwik K Branski; Juan P Barret; Peter Dziewulski; David N Herndon
Journal:  Lancet       Date:  2016-10-01       Impact factor: 79.321

8.  Local Expression of Indoleamine 2,3, Dioxygenase Prolongs Allogenic Skin Graft Take in a Mouse Model.

Authors:  Mohammadreza Pakyari; Ali Farokhi; Reza B Jalili; Ruhangiz T Kilani; Erin Brown; Aziz Ghahary
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-02-13       Impact factor: 4.730

9.  Novel, silver-ion-releasing nanofibrous scaffolds exhibit excellent antibacterial efficacy without the use of silver nanoparticles.

Authors:  Mahsa Mohiti-Asli; Behnam Pourdeyhimi; Elizabeth G Loboa
Journal:  Acta Biomater       Date:  2013-12-21       Impact factor: 8.947

10.  Rigenera protocol in the treatment of surgical wound dehiscence.

Authors:  Marco Marcarelli; Letizia Trovato; Elvio Novarese; Michele Riccio; Antonio Graziano
Journal:  Int Wound J       Date:  2016-04-29       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.